Streetbeat News

Stock Prices

BNTX

BioNTech Inc. (NASDAQ:BNTX) saw a 2.30% drop in its share price to $109.31, despite an 8.87% increase over the past month. The stock has fallen 28.21% over the past year. Investors are examining BioNTech's P/E ratio, which at 9.08 is lower than the Biotechnology industry average of 40.76. This could suggest that BioNTech is undervalued compared to its peers or that investors expect lower future growth. The P/E ratio is a critical metric but should be used alongside other analyses for investment decisions.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:45 pm

POST

Mizuho Securities analyst John J. Baumgartner initiated coverage on Post Holdings Inc (NYSE:POST) with a Buy rating and a $110 price target. Baumgartner highlights POST's strategic acquisitions, alternative structures for enhancing returns, diversified portfolio, and strong cash returns. The company's value-oriented portfolio is seen as well-positioned for consumer economization, with potential for long-term EBITDA growth, especially in the pet category. POST shares saw a slight increase of 0.78% to $93.39.

Portfolio Pulse from Shivani Kumaresan

January 09, 2024 | 6:41 pm

MRK

MRNA

MYNZ

PFE

Pharmaceutical companies Moderna, Pfizer, and Mainz Biomed are shifting focus to cancer treatment and early detection. Moderna's cancer vaccine and Pfizer's acquisition of Seagan aim to accelerate oncology efforts. Mainz Biomed's ColoAlert® shows promise in colorectal cancer (CRC) early detection with high sensitivity and specificity. Moderna's vaccine, combined with Merck's Keytruda, reduced the risk of late-stage skin cancer recurrence. Despite a drop in COVID-19 vaccine sales, Moderna expects sales growth in 2025. The companies are leveraging mRNA technology for personalized cancer treatment, signaling a new era of pharmaceutical innovation.

Portfolio Pulse from Upwallstreet

January 09, 2024 | 6:40 pm

AVIR

Atea Pharmaceuticals Inc (NASDAQ:AVIR) reported a 98% sustained virologic response at week four in a Phase 2 study of bemnifosbuvir and ruzasvir for HCV, exceeding the >90% efficacy criterion. The study showed rapid viral load reduction, supporting an eight-week treatment regimen. The Phase 2 study is ongoing, with full enrollment expected by mid-2024 and topline results in Q3 2024. Atea is also conducting a Phase 3 SUNRISE-3 trial for COVID-19, with the first interim analysis expected in March. William Blair noted the substantial market potential for COVID-19 oral antivirals. Atea's stock rose 9.02% to $3.38.

Portfolio Pulse from Vandana Singh

January 09, 2024 | 6:33 pm

VLO

Financial giants have shown a bullish stance on Valero Energy (NYSE:VLO) based on recent options trades. Analysis of Valero Energy's options history revealed 9 unusual trades, with a majority being bullish. The trades suggest a focus on a price range of $95.0 to $135.0 for VLO. The company is a major independent refiner with significant operations in the US, Canada, and the UK. Currently, VLO's stock price is down by -1.28% at $127.62, and the RSI indicates it may be approaching overbought territory. The next earnings report is due in 16 days.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:31 pm

ECL

Ecolab (NYSE:ECL) has delivered an average annual return of 10.39% over the past 20 years, outperforming the market by 3.01% annually. A $100 investment in ECL 20 years ago would be worth $733.67 today. Ecolab's market capitalization currently stands at $55.79 billion.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:30 pm

NUE

Over the past 5 years, Nucor (NYSE:NUE) has produced an average annual return of 24.68%, outperforming the market by 11.68%. A $1000 investment in NUE 5 years ago would now be worth $2,995.41. Nucor's market capitalization stands at $42.47 billion.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:30 pm

BGNE

BeiGene's stock is trading higher following the announcement that the FDA has approved a label update for its cancer drug BRUKINSA. This regulatory milestone is likely to be viewed positively by investors as it may enhance the drug's marketability and potentially increase sales.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 6:23 pm

DASH

DoorDash shares have risen following an Outperform rating and $120 price target initiation by BMO Capital.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 6:21 pm

ADA-USD

AVAX-USD

SHIB-USD

SOL-USD

XRP-USD

The cryptocurrency market is experiencing notable activity with a 588% surge in Shiba Inu's burn rate and a 1,300% increase in whale transactions. Solana's ecosystem boasts over 2,500 monthly active developers. Solana (SOL) and Avalanche (AVAX) are up in trading, while memecoins Bonk (BONK) and Celestia (TIA) have seen significant increases. XRP saw a large transfer of 100 million coins. Crypto analyst Ali Martinez predicts a potential bull run for Solana and a consolidation period for Cardano (ADA) until April 2024, with a possible resumption of a bull run thereafter. He also notes that the negative market sentiment for XRP could offer unique opportunities.

Portfolio Pulse from Khyathi Dalal

January 09, 2024 | 6:20 pm